Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLANTIC: Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment
NCT04691622Phase 1Recruiting
- Sponsor
- Children's National Research Institute
- Start
- Mar 2022
- Primary completion
- Aug 2028
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of norovirus-specific T-cell therapy in norovirus infection (2 arms), sponsored by Children's National Research Institute. Primary endpoints: Incidence of acute Graft-versus-Host Disease (grade III-IV) at 45 days, Incidence of infusion related adverse events at 45 days and 1 more. Started Mar 2022; status: recruiting.
02
Drugs
norovirus-specific T-cell therapy
03
Conditions
norovirus infection
Beyond the preview
Go deeper on NCT04691622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04691622.